17 results about "Polyadenylic acid" patented technology

The invention relates to the technical field of bioinformatics, in particular to a method for identifying RNA (Ribonucleic Acid) from a transposon element based on RNA sequencing data. According to the invention, the exon level of the teRNA is taken as an analysis object, compared with a teRNA site, the teRNA exon not only realizes more accurate site identification, but also retains the existing form of TE in a transcription product, including whether a splicing site and a polyadenylic acid signal are provided or not, whether the TE is chimeric with a gene or other TE sites or not and the like. And compared with the level of the teRNA transcript, as a constituent part of the transcript, the teRNA exon significantly reduces the sequence assembly difficulty of the short-read-length sequencing data. According to the method, the Bayesian model, the parametric assembly algorithm and the local site de novo assembly algorithm are combined, and through mutual correction of different assembly algorithms and repeated comparison sequencing reading length before and after assembly, the assembly false positive is reduced, so that the teRNA recognition accuracy is improved.

The invention discloses an oligonucleotide intracellular nano delivery system based on polypeptide modification and application thereof. The system is composed of a periostin targeting sequence (SDSSD), a matrix metalloproteinase 2 (MMP2) response sequence (GPAGLLG), a cell penetrating sequence (RRRRRRRR, R9), a reactive oxygen species (ROS) scavenging and adhesion enhancing group (Gly-DOPA)) and a terminal dibenzocyclooctyne (DBCO) modified engineered polypeptide SDSSD-PEG5-YGFGG-GPAGLLG-R9-(G-DOPA) 3-K4-C-DBCO, and a target oligonucleotide miRNA-26a-A5-Azido modified by 5-polyadenylic acid (AAAAA) and an azide group (Azido), and the target oligonucleotide miRNA-26a-A5-Azido, the target oligonucleotide and assembling through a click chemical reaction and a non-covalent interaction. The nano system has good bone targeting, enzyme responsiveness, intracellular delivery effect and biological safety, can realize stable and efficient delivery of therapeutic oligonucleotides in vivo, and significantly improves the utilization efficiency and therapeutic potential of oligonucleotides. The oligonucleotide intracellular nano delivery system has a wide application prospect in the fields of clinical transformation and precise treatment of oligonucleotide drugs.

The invention relates to a KASP molecular marker of a wheat quality related gene TaSF3B4 and application of the KASP molecular marker. The KASP molecular marker is KASP-TaSF3B4, and an SNP (Single Nucleotide Polymorphism) site (A / G) is detected at 248421161bp of a wheat 3B chromosome, namely, the distance between a TaSF3B4 promoter region and an initiation codon is 1127bp. According to the marker, a TaSF3B4 gene influencing the wheat quality character is obtained according to a way that differentially expressed genes in 15d transcriptome data of a grain extreme material are extremely remarkably enriched to a spliceosome, and regular SNP loci exist through sequence comparison and analysis of the TaSF3B4 genes in different varieties and upstream and downstream sequences of the TaSF3B4 genes. The functional KASP molecular marker of the wheat poly (adenylic acid binding protein) gene TaSF3B4 provided by the invention can be used for identifying whether TaSF3B4 excellent alleles exist in wheat varieties / strains or not, and can be applied to assisted selective breeding and pyramiding breeding of other genes related to known quality.

The invention discloses a macrophage immune activation method based on aggregate mediated magnesium ion delivery. The method comprises the following steps: in a buffer environment containing magnesium ions, preparing a biomolecular aggregate formed by compounding polyarginine and polyadenylic acid through liquid-liquid phase separation, and enriching the magnesium ions by the aggregate through multivalent chelation; diluting the aggregate loaded with high-concentration magnesium ions in a cell culture medium to obtain a biomolecular aggregate suspension; and sequentially adding the target cell suspension and the biomolecular aggregate suspension into a cell culture dish, fully mixing, and then transferring the cell culture dish into a carbon dioxide cell incubator for standing culture. According to the method, the biomolecular aggregate loaded with the high-concentration magnesium ions is co-cultured with the cells, and the high-concentration magnesium ions are delivered into the cells in a short time, so that the immune level of the cells is improved, and the activity and safety of the cells are ensured.

The present invention relates to a template DNA molecule for in vitro transcription, the mRNA obtained by transcribing according to the template DNA molecule, its preparation method and the application of the mRNA in disease prevention and treatment, wherein the template DNA molecule sequentially includes a promoter, a 5'-untranslated region (5'UTR), a Kozak sequence, a polypeptide or protein coding region, a 3'-untranslated region (3'UTR) and a polyadenylic acid (polyA) sequence; through the promoter, the 5'-untranslated region, the Kozak sequence, the polypeptide or protein coding region, the 3'-untranslated region and the polyadenylic acid sequence can be co-transcribed to produce a co-transcript. The template DNA molecule or mRNA molecule provided by the present invention can be used to prepare vaccines and drugs for treating diseases.

The invention provides polynucleotide constructs for the regulation of gene expression by aptamer-based modulation of U1 small nuclear ribonucleoprotein (snRNP)-mediated suppression of polyadenylation and methods of using the constructs to regulate gene expression in response to the presence or absence of a ligand that binds the aptamer. The polynucleotide construct contains a U1 binding site in the context of a riboswitch comprising an effector region and an aptamer such that when the aptamer binds a ligand, target gene expression occurs.

The present invention relates to the field of in-vitro transcription, in particular to a plasmid backbone capable of improving the stability of the polyadenylic acid tail. Provided is an expression cassette, sequentially comprising: a rop gene, a replicon ori, and a resistance gene, wherein the rop gene, the replicon ori, and the resistance gene are connected by means of linker fragments. Low-copy pmRVacSL and medium-copy pmRVacM plasmid vector systems are established by means of artificial modification. Since pmRVacSL is a low-copy vector, the plasmid DNA yield is relatively low. The pmRVacM plasmid backbone addresses the problem of low plasmid DNA yield of pmRVacSL. The vector system not only enables stable replication of polyA tail sequences of 150 bp or more, but also allows for rapid addition of genes of interest and polyadenylic acid (polyA) sequences, efficiently and rapidly obtaining the target DNA template for mRNA in vitro transcription.

A partially or fully differentiated iPSC-derived microglia cell comprising a transposon comprising a Ubiquitous Chromatin Opening Element (UCOE) nucleic acid sequence, and a nucleic acid sequence of a gene of interest or a fragment thereof and optionally a 3' polyadenylation sequence under control of a promoter, flanked by transposon-specific inverted terminal repeat sequences 5' ITR and 3' ITR.

The invention discloses a method for fixed-point integration of a fluorescence report at a duck W chromosome EE0.6 site, and relates to the technical field of gene editing. The method comprises the following steps: transfecting an exogenous report element, an sgRNA expression vector and an spCas9-Puro expression vector into duck cells; the sgRNA expression vector comprises sgRNA of an EE0.6 site in a duck W chromosome in a targeting manner. The exogenous reporter element comprises a sequence A, an EF1 alpha promoter, an eGFP (enhanced green fluorescent protein) gene, an SV40 polyadenylic acid polyA, an SV40 promoter, a Neo resistance gene, an HSV-TK polyadenylic acid polyA, the sequence A and an sgRNA (single guide ribonucleic acid) expression element which is started by an hU6 promoter and aims at the sequence A, which are connected in sequence. According to the method, the exogenous eGFP gene can be efficiently integrated to the duck W chromosome EE0.6 site in a site-specific manner through an NHEJ way, and the method has important significance in duck sex identification and deep scientific research.

The present invention relates to compositions and kits and to methods, and uses of any thereof to accurately and precisely assay the size in terms of number of adenosines and the size distribution of polyadenylic acid (“polyA” or “poly(A)” tails) on the 3′-end portions of RNA molecules.

The invention discloses an mRNA drug capable of expressing horse follicle-stimulating hormone, a preparation method and application thereof, and belongs to the technical field of therapeutic drugs, the mRNA drug comprises an mRNA molecule and a drug carrier, the mRNA molecule comprises a 5'terminal untranslated region, a coding RNA gene of horse follicle-stimulating hormone protein, a 3 'terminal untranslated region and polyadenylic acid, and the drug carrier comprises lipid nanoparticles; compared with the prior art, the invention develops a novel follicle-stimulating hormone supplementing method by taking mRNA as a way, and has the characteristics of high flexibility, safety and efficiency.

The invention discloses a plasma nano antenna array substrate based on DNA origami, a preparation method and application, and the substrate comprises a DNA origami probe array composed of a rectangular DNA origami nano structure, a functional probe modified at a specific site of the rectangular DNA origami nano structure, and an extension chain, the plasma nano antenna array substrate is formed by using the extension chain and the micro-fluidic silver nanoparticle array in complementary connection with the extension chain through polyadenylic acid, and is used for dynamic analysis of serum biomarkers, so that the detection efficiency is improved.

Disclosed are a nucleic acid molecule, and a recombinant nucleic acid molecule comprising the nucleic acid molecule, a nucleic acid sequence encoding a foreign protein, and a polyadenylic acid sequence (i.e. PolyA). The invention also discloses a recombinant adeno-associated virus, which comprises an AAV capsid and a vector genome, and the vector genome comprises the recombinant nucleic acid molecule. Also disclosed is the use of the recombinant adeno-associated virus for more effective treatment of spinal cord injury.

The present invention discloses an mRNA molecule for protein targeted degradation and its application. The mRNA molecule for protein targeted degradation disclosed in the present invention includes a 5' cap structure, a 5' non-coding region, a Kozak element, a coding region, a 3' non-coding region and a polyadenylic acid structure in sequence, wherein the coding region includes a functional polypeptide encoding gene, and the functional polypeptide includes a VHL E3 ubiquitin ligase targeting peptide, a connecting peptide and a target protein targeting polypeptide connected in sequence. The mRNA molecule for protein targeted degradation of the present invention has higher safety, can improve the anti-tumor efficacy of peptide PROTACs, solves the key cell penetration problem, can efficiently target and degrade the target protein, and provides a new protein targeted degradation molecular pattern with broad application prospects.

The invention discloses a low-immunogenicity iPSC cell based on CIITA gene knockout and tEGFR gene knockin as well as a preparation method and application of the low-immunogenicity iPSC cell. A double-stranded DNA template for targeted knockin of a tEGFR gene at a CIITA gene knockout site sequentially comprises a CIITA left homologous arm, a CMV enhancer, a chicken beta-actin promoter, a chimeric intron, a Kozak sequence, a CSF2RA signal peptide, a tEGFR gene, a bGH polyadenylic acid signal and a CIITA right homologous arm from upstream to downstream; the left homologous arm and the right homologous arm are used for determining the position of a double-stranded DNA template, the DNA of the left homologous arm is homologous with the 5'end sequence of a DNA incision targeted by gene fixed-point knock-in, the right homologous arm is homologous with the 3 'end sequence of the DNA incision, and the CMV enhancer and the chicken beta-actin promoter form an exogenous promoter (CAG promoter) for driving the expression of the knocked-in tEGFR gene.

The present application relates to the structure and a use of a plasmid containing polyadenylic acid (polyA). The isolated nucleic acid molecule involved in the present application comprises the following components: an origin of replication sequence, a first transition sequence, and a site-specific recombination sequence. The present application further relates to a vector comprising the nucleic acid molecule, a host cell comprising the nucleic acid molecule and / or the vector, and a diagnostic or pharmaceutical composition and a kit comprising the nucleic acid molecule, the vector and / or the host cell. The present application further provides a method for expressing a target gene.